Drug Trial Radar · NCT06795412
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
Apr 15, 2025
Primary completion
Dec 6, 2027
Study completion Dec 6, 2027
Sponsor
- Lead sponsor
- Pyxis Oncology, IncIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jan 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
PYX-201Drug
Intravenous (IV) infusion.
pembrolizumabDrug
IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants who Experience a Dose-Limiting Toxicity (DLT)Time frame: Day 1 to Day 21
- Number of Participants who Experience an Adverse Event (AE)Time frame: Up to approximately 2 years
- Number of Participants who Experience Clinically Significant Changes in Clinical Laboratory ParametersTime frame: Up to approximately 2 years
- Number of Participants who Experience Clinically Significant Changes in Vital SignsTime frame: Up to approximately 2 years
- Number of Participants who Experience Clinically Significant Changes in electrocardiogram (ECG) ParametersTime frame: Up to approximately 2 years
Locations
22 sites in 3 countries. Site status is shown where the registry gives one.
University of California San Diego
San Diego, California · Recruiting
Sarcoma Oncology Center
Santa Monica, California · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
University of Chicago
Chicago, Illinois · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Stephenson Cancer Center - University of Oklahoma
Oklahoma City, Oklahoma · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Recruiting
University of Texas - M.D. Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Oncology Houston
Houston, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Hopital Saint - Andre - CHU de Bordeaux
Bordeaux, France · Recruiting
Centre Léon Bérard
Lyon, France · Recruiting
Hôpital de la Timone
Marseille, France · Recruiting
Institut Gustave Roussy
Villejuif, France · Recruiting
Hospital Universitario Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital Universitario Ramón y Cajal
Madrid, Spain · Recruiting
START Madrid - Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Clínico Universitario de Valencia
Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.